A biobank within the Swedish national heart failure quality registry SwedeHF.
Written informed consent
Heart failure defined by symptoms and signs of heart failure as judged by the local investigator
Registered in SwedeHF
Plasma donation within 1 month of enrolment or any blood donation/blood loss >500 mL during the 3 months prior to enrolment
Previous allogeneic bone marrow transplant (genetics)
In the opinion of the investigator, condition/s that may either put the patient at risk on participation or influence the results or the patient's ability to participate in the study.
PAtients with heart failure in Sweden with a registration in SwedeHF.
Cohort
Prospective
Not listed
Identify responders to guideline-directed medical therapy
To identify which patient will be a non-responder resulting in a poor outcome, despite being on recommended treatment according to guidelines.
Differences in morbidity between responders and non-responders to guideline-directed medical therapy
To characterize differences between responders and non-responders in terms of morbidity after 2-years follow-up.
Differences in mortality between responders and non-responders to guideline-directed medical therapy
To characterize differences between responders and non-responders in terms of mortality after 2-years follow-up.
Predictors of responders and non-responders to guideline-directed medical therapy
To integrate information regarding clinical characteristics, diagnostic markers and genetics to determine underlying mechanisms behind different responses to treatment.
Differences between responders and non-responders regarding mortality
To evaluate the differences between HFrEF and HFpEF patients in terms of mortality and after 2 and 5 years follow-up, respectively.
Differences between responders and non-responders regarding morbidity
o evaluate the differences between HFrEF and HFpEF patients in terms of morbidity after 2 and 5 years follow-up, respectively.
Predictors of mortality in responders and non-responders
To evaluate the differences in mortality between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets.
Predictors of morbidity in responders and non-responders
To evaluate the differences in morbidity between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets.
Click on the lead sponsor to view all of their trials.
Karolinska University Hospital
Lead sponsor
University Hospital, Linkoeping
Collaborator
